Qualitative Analysis of PAIN in Patients with Locally Advanced or Metastatic Urothelial Cancer

Author(s)

Shah SN1, Hepp Z2, Martin S3, Harris N3, Morgans A4
1Astellas Pharma, Inc., Northbrook, IL, USA, 2Seattle Genetics, Bothell, WA, USA, 3RTI International, Raleigh, NC, USA, 4Northwestern University Feinberg School of Medicine, Evanston, IL, USA

OBJECTIVES

To characterize pain and its impact in patients with locally advanced or metastatic urothelial cancer (la/mUC) treated in the first-line setting and to assess the content validity of the Brief Pain Inventory Short Form (BPI-SF) worst pain item in this population.

METHODS

One-hour semi-structured qualitative interviews were conducted in US patients meeting these criteria: aged ≥45 years, physician-confirmed la/mUC receiving first-line treatment, self-reported la/mUC-attributed pain >0 (0 [none] to 10 [as bad as you can imagine] scale) prior to enrollment, and no major surgeries ≤3 months prior to the interview. Patients were asked open-ended questions about their la/mUC symptoms and la/mUC pain (eg, location, impacts on their life); areas of interest not spontaneously mentioned were probed. “Think aloud” cognitive debriefing was conducted for the BPI-SF worst pain item.

RESULTS

Sixteen patients (laUC, n=10; mUC, n=6) were interviewed (mean age, 53.8 years; male, n=8). All patients were diagnosed within ≤5 (mean, 2.73) months of study entry. First-line treatments included cisplatin-containing (n=14) or carboplatin-gemcitabine (n=2) therapies. The average past-week worst pain score was 6.2 (range, 3-10). Pain was the most commonly reported symptom (n=16) related to la/mUC. Pain was frequently reported in the back (n=14) and pelvic/lower abdominal area (n=10). All patients reported that pain impacted their physical and daily activities and most (n=13) reported it impacted overall quality of life. All patients correctly interpreted and easily completed the BPI-SF worst pain item; 15 reported that it was relevant to their la/mUC experience. Patients understood the 24-hour recall period; most supported daily (n=13) or weekly (n=14) assessment and preferred electronic administration using their device (n=14).

CONCLUSIONS

In patients with la/mUC-attributed pain receiving first-line treatment, these results indicate that pain impacts patients’ lives, including physical and daily activities, and demonstrates BPI-SF worst pain item content validity in this population.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PCN326

Topic

Patient-Centered Research

Topic Subcategory

Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×